Association of adiponectin, resistin, and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 4, 2011, Pages 944-949

  Choi, Hae Yoon ^a   Kim, Sungeun ^b   Yang, Sae Jeong ^a   Yoo, Hye Jin ^a   Seo, Ji A ^a   Kim, Sin Gon ^a   Kim, Nan Hee ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Choi, Kyung Mook ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

adiponectin; inflammation; positron emission tomography; resistin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RESISTIN; RISK ASSESSMENT; RISK FACTORS;

EID: 79953744702     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.220673     Document Type: Article

References (39)

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516. (Pubitemid 32201946)
2. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991;87:87-90.
3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44. (Pubitemid 24026469)
4. Ben-Haim S, Israel O. PET/CT for atherosclerotic plaque imaging. Q J Nucl Med Mol Imaging. 2006;50:53-60.
5. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-451. (Pubitemid 40686653)
6. Stefan N, Stumvoll M. Adiponectin: its role in metabolism and beyond. Horm Metab Res. 2002;34:469-474. (Pubitemid 35192231)
7. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005; 6:7-14.
8. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226-228. (Pubitemid 36126226)
9. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005;54:534-539.
10. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737. (Pubitemid 38489895)
11. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312. (Pubitemid 32151228)
12. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133:157-170.
13. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005; 111:932-939. (Pubitemid 40279897)
14. Chen W, Bural GG, Torigian DA, Rader DJ, Alavi A. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2009;36:144-151.
15. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-1824. (Pubitemid 44648622)
16. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105:2708-2711. (Pubitemid 34615139)
17. Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18Ffluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142-148.
18. van der Wall EE, Schuijf JD, Jukema JW, Bax JJ, van der Laarse A. Atherosclerotic plaque imaging by pet/ct; can inactive, active and mixed plaques be discerned? Int J Cardiovasc Imaging. 2009;25:141-144.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance andβ-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419. (Pubitemid 15018832)
21. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR activators. Biochem Biophys Res Commun. 2003;300:472-476. (Pubitemid 38375833)
22. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001; 98:502-506. (Pubitemid 32105071)
23. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-β action in humans. Diabetes. 2001;50:2199-2202. (Pubitemid 33641901)
24. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun. 2003;310:927-935. (Pubitemid 37188711)
25. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415-419. (Pubitemid 38084733)
26. Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, Hsiao SH, Pan CC, Kou YR, Hsu YP, Ho LT. Resistin increases lipid accumulation by affecting class a scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci. 2009;84:97-104.
27. Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol. 2008;159:585-593.
28. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz Wika J, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism. 2008;57:488-493. (Pubitemid 351317962)
29. Weikert C, Westphal S, Berger K, Dierkes J, Mohlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008;93:2647-2653. (Pubitemid 352008532)
30. Lee SH, Ha JW, Kim JS, Choi EY, Park S, Kang SM, Choi D, Jang Y, Chung N. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis. 2009;20:33-39.
31. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006;16:141-146. (Pubitemid 43867326)
32. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167:1510-1517. (Pubitemid 47124181)
33. Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007;154:750.e1-e7.
34. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109:III33-III38. (Pubitemid 38786441)
35. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, Kudomi N, Shiomi M, Magata Y, Iida H, Saji H. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and pet imaging study. J Nucl Med. 2004;45:1245-1250. (Pubitemid 47611672)
36. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207:139-143.
37. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50:892-896. (Pubitemid 47268746)
38. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49: 1533-1539. (Pubitemid 46517964)
39. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50: 1611-1620.